Palatin Technologies (OTCMKTS:PTNT) Stock Falls 1.9% – Here’s Why

Shares of Palatin Technologies, Inc. (OTCMKTS:PTNT – Get Free Report) fell 1.9% on Monday. The stock traded as low as $24.33 and last traded at $24.33. Approximately 15 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 663 shares. The stock had previously closed at $24.81.

Palatin Technologies Price Performance

The company has a market capitalization of $973,200.00, a P/E ratio of -15.70 and a beta of -1.04. The stock has a 50-day moving average price of $24.45 and a 200-day moving average price of $19.29.

About Palatin Technologies

(Get Free Report)

Palatin Technologies is a biopharmaceutical company focused on developing medicines that act on melanocortin and other peptide-receptor systems. Its research has targeted conditions in areas including sexual health, inflammation and eye disease. The company’s best-known product is Vyleesi (bremelanotide), a prescription treatment approved in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Palatin has also pursued investigational candidates for inflammatory conditions and dry eye disease; these candidates are not approved treatments.

Further Reading

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.